Chemotherapy, Cardiovascular Disease, and Cardiac Tumors

  • Jims Jean-Jacques
  • Eugene Storozynsky


Cardiac disease and cancer are the two most common medical conditions in the developed world. The rates of death for heart disease and malignant neoplasms remain very high. As we age, they tend to coexist. Cancer can affect the heart as metastasis, or due to the complexity of the heart, cancer can directly emanate from within the heart as a benign growth or malignant neoplasm. As cancer treatments have become more and more successful over the years, it is important to realize that some of these advances have led to increased cardiovascular morbidity and mortality due to the development of unintended cardiac side effects. This chapter summarizes chemotherapeutic and radiotherapeutic interventions most commonly associated with cardiovascular disease (CVD), recommendations for surveillance monitoring, possible treatments, and cardiac tumors that the general cardiologist should be aware of during routine consultation and office-based care.


Chemotherapy Imaging Surveillance Treatment Cardiac tumors 


  1. 1.
    Oeffinger KC, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–82.CrossRefPubMedGoogle Scholar
  2. 2.
    Meinardi MT, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev. 1999;25:237–47.CrossRefPubMedGoogle Scholar
  3. 3.
    Albini A, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Boerman LM, et al. Long-term follow-up for cardiovascular disease after chemotherapy and/or radiotherapy for breast cancer in an unselected population. Support. Care Cancer. 2014;22:1949–58.Google Scholar
  5. 5.
    Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900.CrossRefPubMedGoogle Scholar
  6. 6.
    Guglin M, Aljayeh M, Saiyad S, et al. Introducing a new entity: chemotherapy-induced arrhythmia. Europace. 2009;11:1579.CrossRefPubMedGoogle Scholar
  7. 7.
    Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47.CrossRefPubMedGoogle Scholar
  8. 8.
    Steinberg JS, Cohen AJ, Wasserman AG, et al. Acute arrhythmogenicity of doxorubicin administration. Cancer. 1987;60:1213.CrossRefPubMedGoogle Scholar
  9. 9.
    Barrett-Lee PJ, Dixon JM, Farrell C, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009;20:816.CrossRefPubMedGoogle Scholar
  10. 10.
    Bovelli D, Plataniotis G, Roila F, On behalf of the ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21:277–82.CrossRefGoogle Scholar
  11. 11.
    MInotti G, et al. Anthracyclines. In: Offermanns S, Rosenthal W, editors. Encyclopedia of molecular pharmacology, vol. 1. 2nd ed: Springer; 2008.Google Scholar
  12. 12.
    Takimoto CH, Calvo E. Principles of oncologic pharmacotherapy. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, editors. Cancer management: a multidisciplinary approach. 11th ed. London, UK: UBM Medica; 2008.Google Scholar
  13. 13.
    Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res. 2016;118(6):1008–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332–44.CrossRefPubMedGoogle Scholar
  17. 17.
    Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;118:84–95.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86:1697.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Schwartz RG, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J Nucl Cardiol. 2013;20:443–64.CrossRefPubMedGoogle Scholar
  20. 20.
    Storozynsky E. Multimodality assessment and treatment of chemotherapy-induced cardiotoxicity. Futur Cardiol. 2015;11(4):421–4.CrossRefGoogle Scholar
  21. 21.
    Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911.CrossRefPubMedGoogle Scholar
  22. 22.
    Bruce CJ. Cardiac tumours: diagnosis and management. Heart. 2011;97(2):151–60.CrossRefPubMedGoogle Scholar
  23. 23.
    Lam KY, Dickens P, Chan AC. Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med. 1993;117:1027e31.Google Scholar
  24. 24.
    Piazza N, Chughtai T, Toledano K, et al. Primary cardiac tumours: eighteen years of surgical experience on 21 patients. Can J Cardiol. 2004;20:1443e8.Google Scholar
  25. 25.
    Vander Salm TJ. Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg. 2000;12:89.CrossRefPubMedGoogle Scholar
  26. 26.
    Elbardissi AW, Dearani JA, Daly RC, et al. Embolic potential of cardiac tumors and outcome after resection: a case-control study. Stroke. 2009;40:156.CrossRefPubMedGoogle Scholar
  27. 27.
    Sheu CC, Lin SF, Chiu CC, et al. Left atrial sarcoma mimicking obstructive pulmonary disease. J Clin Oncol. 2007;25:1277.CrossRefPubMedGoogle Scholar
  28. 28.
    Engberding R, Daniel WG, Erbel R, et al. Diagnosis of heart tumours by transoesophageal echocardiography: a multicentre study in 154 patients. European Cooperative Study Group. Eur Heart J. 1993;14:1223.CrossRefPubMedGoogle Scholar
  29. 29.
    Dujardin KS, Click RL, Oh JK. The role of intraoperative transesophageal echocardiography in patients undergoing cardiac mass removal. J Am Soc Echocardiogr. 2000;13(12):1080–3.CrossRefPubMedGoogle Scholar
  30. 30.
    de Lucas EM, Pagola MA, Fernández F, et al. Primary cardiac lymphoma: helical CT findings and radiopathologic correlation. Cardiovasc Intervent Radiol. 2004;27:190.PubMedGoogle Scholar
  31. 31.
    Araoz PA, Eklund HE, Welch TJ, Breen JF. CT and MR imaging of primary cardiac malignancies. Radiographics. 1999;19:1421.CrossRefPubMedGoogle Scholar
  32. 32.
    Hoey ET, Mankad K, Puppala S, et al. MRI and CT appearances of cardiac tumours in adults. Clin Radiol. 2009;64:1214.CrossRefPubMedGoogle Scholar
  33. 33.
    Siripornpitak S, Higgins CB. MRI of primary malignant cardiovascular tumors. J Comput Assist Tomogr. 1997;21:462.CrossRefPubMedGoogle Scholar
  34. 34.
    Wintersperger BJ, Becker CR, Gulbins H, et al. Tumors of the cardiac valves: imaging findings in magnetic resonance imaging, electron beam computed tomography, and echocardiography. Eur Radiol. 2000;10:443.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Jims Jean-Jacques
    • 1
  • Eugene Storozynsky
    • 2
  1. 1.St. Joseph Cardiology DepartmentSt. Joseph HospitalBangorUSA
  2. 2.University of Rochester Medical Center/CardiologyRochesterUSA

Personalised recommendations